Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 183

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study

Open access
Rijnsburger, Adriana J., Obdeijn, Inge-Marie, Kaas, Reinoutje, Tilanus-Linthorst, Madeleine M.A., Boetes, Carla, Loo, Claudette E., Wasser, Martin N.J.M., Bergers, Elisabeth, Kok, Theo, Muller, Sara H., Peterse, Hans, Tollenaar, Rob A.E.M., Hoogerbrugge, Nicoline, Meijer, Sybren, Bartels, Carina C.M., Seynaeve, Caroline, Hooning, Maartje J., Kriege, Mieke, Schmitz, Paul I. M., Oosterwijk, Jan C., de Koning, Harry J., Rutgers, Emiel J.T., Klijn, Jan G.M. · 2010 · Journal of Clinical Oncology

Abstract

Purpose: The Dutch MRI Screening Study on early detection of hereditary breast cancer started in 1999. We evaluated the long-term results including separate analyses of BRCA1 and BRCA2 mutation carriers and first results on survival. Patients and Methods: Women with higher than 15% cumulative lifetime risk (CLTR) of breast cancer were screened with biannual clinical breast examination and annual mammography and magnetic resonance imaging (MRI). Participants were divided into subgroups: carriers of a gene mutation (50% to 85% CLTR) and two familial groups with high (30% to 50% CLTR) or moderate risk (15% to 30% CLTR). Results: Our update contains 2,157 eligible women including 599 mutation carriers (median follow-up of 4.9 years from entry) with 97 primary breast cancers detected (median follow-up of 5.0 years from diagnosis). MRI sensitivity was superior to that of mammography for invasive cancer (77.4% v 35.5%; P < .00005), but not for ductal carcinoma in situ. Results in the BRCA1 group were worse compared to the BRCA2, the high-, and the moderate-risk groups, respectively, for mammography sensitivity (25.0% v 61.5%, 45.5%, 46.7%), tumor size at diagnosis ≤ 1 cm (21.4% v 61.5%, 40.9%, 63.6%), proportion of DCIS (6.5% v 18.8%, 14.8%, 31.3%) and interval cancers (32.3% v 6.3%, 3.7%, 6.3%), and age at diagnosis younger than 30 years (9.7% v 0%). Cumulative distant metastasis-free and overall survival at 6 years in all 42 BRCA1/2 mutation carriers with invasive breast cancer were 83.9% (95% CI, 64.1% to 93.3%) and 92.7% (95% CI, 79.0% to 97.6%), respectively, and 100% in the familial groups (n = 43). Conclusion: Screening results were somewhat worse in BRCA1 mutation carriers, but 6-year survival was high in all risk groups.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2009.27.2294

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 183

Metadata

Authors
Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus-Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., Peterse, H., Tollenaar, R. A. E. M., Hoogerbrugge, N., Meijer, S., Bartels, C. C. M., Seynaeve, C., Hooning, M. J., Kriege, M., Schmitz, P. I. M., Oosterwijk, J. C., de Koning, H. J., Rutgers, E. J. T., & Klijn, J. G. M.
Venue
Journal of Clinical Oncology
Published
2010-12-20
Volume
28
Issue
36
Pages
5265-5273
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2172296348
Cited by
183
References
5
FWCI
8.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. https://app.cochat.ai/papers/10.1200/jco.2009.27.2294
The paper
Rijnsburger, A. J., Obdeijn, I.-M., Kaas, R., Tilanus-Linthorst, M. M. A., Boetes, C., Loo, C. E., Wasser, M. N. J. M., Bergers, E., Kok, T., Muller, S. H., Peterse, H., Tollenaar, R. A. E. M., Hoogerbrugge, N., Meijer, S., Bartels, C. C. M., Seynaeve, C., Hooning, M. J., Kriege, M., Schmitz, P. I. M., . . . Klijn, J. G. M. (2010). BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2009.27.2294

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.